IL149810A0 - Method of enhancing immune responses to herpes simplex virus vaccine - Google Patents

Method of enhancing immune responses to herpes simplex virus vaccine

Info

Publication number
IL149810A0
IL149810A0 IL14981000A IL14981000A IL149810A0 IL 149810 A0 IL149810 A0 IL 149810A0 IL 14981000 A IL14981000 A IL 14981000A IL 14981000 A IL14981000 A IL 14981000A IL 149810 A0 IL149810 A0 IL 149810A0
Authority
IL
Israel
Prior art keywords
type
hsv
nucleic acid
protein
mammal
Prior art date
Application number
IL14981000A
Other languages
English (en)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL149810A0 publication Critical patent/IL149810A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14981000A 1999-12-17 2000-12-07 Method of enhancing immune responses to herpes simplex virus vaccine IL149810A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17231399P 1999-12-17 1999-12-17
PCT/US2000/033105 WO2001044477A1 (en) 1999-12-17 2000-12-07 Method of enhancing immune responses to herpes simplex virus vaccine

Publications (1)

Publication Number Publication Date
IL149810A0 true IL149810A0 (en) 2002-11-10

Family

ID=22627181

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14981000A IL149810A0 (en) 1999-12-17 2000-12-07 Method of enhancing immune responses to herpes simplex virus vaccine

Country Status (16)

Country Link
EP (1) EP1238086B1 (xx)
JP (1) JP2003517042A (xx)
KR (1) KR100773390B1 (xx)
CN (1) CN1222619C (xx)
AT (1) ATE319833T1 (xx)
AU (1) AU783730B2 (xx)
BR (1) BR0016419A (xx)
CA (1) CA2406678A1 (xx)
CY (1) CY1105604T1 (xx)
DE (1) DE60026588T2 (xx)
DK (1) DK1238086T3 (xx)
ES (1) ES2258987T3 (xx)
IL (1) IL149810A0 (xx)
MX (1) MXPA02005867A (xx)
PT (1) PT1238086E (xx)
WO (1) WO2001044477A1 (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291365B2 (en) * 2002-11-07 2009-06-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
JP5771605B2 (ja) 2009-05-22 2015-09-02 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法
KR101008582B1 (ko) * 2010-09-20 2011-01-17 (주)칠칠공사 달비계용 2중 안전 샤클조립체
EP2643014A4 (en) 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
EP2782597B1 (en) * 2011-11-23 2022-04-13 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9566325B2 (en) 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
CN110938604B (zh) * 2014-03-03 2024-04-05 阿尔伯特爱因斯坦医学院 重组单纯疱疹病毒2(hsv-2)疫苗载体
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CN104721839A (zh) * 2015-03-17 2015-06-24 浙江省医学科学院 一种预防单纯疱疹病毒ii型的疫苗
CN104830781A (zh) * 2015-05-05 2015-08-12 杨光华 基于hsv-2抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
JP7204653B2 (ja) * 2017-08-30 2023-01-16 Ｋｍバイオロジクス株式会社 改変型ＨＳＶ ｇＤタンパク質及びこれを含むワクチン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275421T1 (de) * 1998-02-12 2004-09-15 Wyeth Corp Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe

Also Published As

Publication number Publication date
CN1434864A (zh) 2003-08-06
KR20020073348A (ko) 2002-09-23
CY1105604T1 (el) 2010-07-28
AU2065101A (en) 2001-06-25
EP1238086A1 (en) 2002-09-11
EP1238086B1 (en) 2006-03-08
ES2258987T3 (es) 2006-09-16
DE60026588D1 (de) 2006-05-04
PT1238086E (pt) 2006-07-31
AU783730B2 (en) 2005-12-01
DE60026588T2 (de) 2007-01-18
BR0016419A (pt) 2002-08-20
MXPA02005867A (es) 2002-10-23
JP2003517042A (ja) 2003-05-20
CN1222619C (zh) 2005-10-12
ATE319833T1 (de) 2006-03-15
DK1238086T3 (da) 2006-06-26
WO2001044477A1 (en) 2001-06-21
KR100773390B1 (ko) 2007-11-09
CA2406678A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
CY1105604T1 (el) Μεθοδος ενισχυσης ανοσων απαντησεων στο εμβολιο κατα του ιου του απλου ερπητα
KR0176265B1 (en) Causative agent of the mystery swine disease, and vaccine compositions
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
CA2660355A1 (en) Polynucleotide vaccine formulation against pathologies of the horse
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
ATE264911T1 (de) Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
EP2172551A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
NZ306653A (en) Isolated dna il-17 receptors
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2002024739A3 (en) Spas-1 cancer antigen
BR0014138A (pt) Uso de um vetor adenoviral deficiente em replicação, e, métodos para reforçar, e para induzir resposta imune de célula cd8+ t a um antìgeno em um indivìduo
DK0587735T3 (da) T-cellereceptorpeptider som terapeutiske midler til immunrelateret sygdom
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
AU8467201A (en) Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
WO1999053960A3 (en) Enhancing immune responses to genetic immunization by using a chemokine
BR0013574A (pt) Antìgeno vacina de moraxella
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
DK0524421T3 (da) Humant herpesvirus type 6 protein p 100, de tilsvarende DNA-sekvenser, deres fremstilling og anvendelse
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
AU7508198A (en) Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
BR0213554A (pt) Timosina para aumento da imunização genética
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
NL300254I1 (nl) Verzwakte herpesvirussen, herpesvirussen die vreemd DNA omvatten dat codeert voor een aminozuur-sequentie en vaccin dat het bevat.
NZ334582A (en) Polyprotein construct of a papillomavirus